Affordable Access

Publisher Website

Advances in Induced Pluripotent Stem Cell Technologies

Stem Cells International
Hindawi Publishing Corporation (Sage-Hindawi Access to Research)
Publication Date
DOI: 10.1155/2012/850201
  • Editorial
  • Computer Science
  • Medicine


Hindawi Publishing Corporation Stem Cells International Volume 2012, Article ID 850201, 1 page doi:10.1155/2012/850201 Editorial Advances in Induced Pluripotent Stem Cell Technologies Rajarshi Pal,1 Mahendra Rao,2 Mohan C. Vemuri,3 Paul Verma,4 and Andras Dinnyes5 1 Manipal Institute of Regenerative Medicine, Manipal University Branch Campus, Bangalore 560 071, India 2 NIH Center for Regenerative Medicine, Bethesda, MD 20892, USA 3 Life Technologies, Frederick, MD 21704, USA 4 Centre for Reproduction and Development, Monash Institute of Medical Research, Monash University, Clayton, VIC 33168, Australia 5 BioTalentum Ltd., Godollo 2100, Hungary Correspondence should be addressed to Rajarshi Pal, [email protected] Received 5 April 2012; Accepted 5 April 2012 Copyright © 2012 Rajarshi Pal et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Progress in studying induced pluripotent stem cell (iPSC) has been extremely rapid. Ever since the remarkable dis- covery of iPSCs by Takahashi and Yamanaka, the field has continued to evolve with exciting discoveries furthering our understanding of early development, the process of cellular reprogramming, acquisition and maintenance of pluripo- tency, determination of cell fate, and enhancing our ability to model diseases in vitro. These advances and the possibility of generating patient or disease specific pluripotent cells placed the field on a trajectory that may lead to personalized cell therapy in the near future. Although there have been significant advances in iPSC- based research, significant challenges remain and these will need to be addressed before tangible outcomes can be realized. Such challenges include developing robust strate- gies to reprogram cells free of a viral/genetic foot print, resolving the immune and potential tumorigenicity issues,

There are no comments yet on this publication. Be the first to share your thoughts.


Seen <100 times